Hearing follows briefing on pharmacotherapies for addiction

On June 23, the Domestic Policy Subcommittee of the House Committee on Oversight and Government Reform held a hearing on "Treating Addiction as a Disease: The Promise of Medication Assisted Recovery"

On June 23, the Domestic Policy Subcommittee of the House Committee on Oversight and Government Reform held a hearing titled "Treating Addiction as a Disease: The Promise of Medication Assisted Recovery." The hearing was a direct result of conversations initiated with subcommittee staff at the May 11 Friends of NIDA coalition briefing on that topic. Dr. Tom McLellan, Deputy Director of the White House Office of National Drug Control Policy and Dr. Nora Volkow, Director of the National Institute on Drug Abuse, both testified in the first panel of witnesses. Although the hearing was focused on pharmacotherapy, Drs. McLellan and Volkow took advantage of every opportunity to cite the critical importance of combining medications with behavioral interventions. A second panel provided testimony covering the patient perspective, medical specialists, local provider networks and pharmaceutical industry. The pharmaceutical industry was represented well by Friends of NIDA co-Chair Charles O’Keefe, who shepherded the development of buprenorphine during his tenure in industry.

View Dr. McLellan’s testimony.

View Dr. Volkow’s testimony.

View Dr. O’Keefe’s testimony.

View all written statements as well as a link to an archived webcast of the hearing.